10-Q: Bausch Health Q2 2026 Earnings: Revenue Up, But Net Loss Widens

Bausch Health Companies Inc. reported a 13% increase in Q2 2026 revenue to $2.85 billion, driven by pricing and acquisitions, but a significant goodwill impairment led to a net loss attributable to the company of $1.17 billion for the six-month period.

Summary

• Bausch Health Companies Inc. reported total revenues of $2.85 billion for the three months ended June 30, 2026, a 13% increase compared to the same period in 2025, driven by improved net realized pricing, acquisitions, and favorable foreign currency impacts.
• For the six months ended June 30, 2026, revenues increased by 12% to $5.38 billion, also attributed to pricing, acquisitions, and foreign currency, though partially offset by lower volumes and divestitures.
• A significant goodwill impairment of $1.43 billion related to the Salix reporting unit negatively impacted the six-month results, contributing to a net loss attributable to Bausch Health Companies Inc. of $1.17 billion.
• The company's operating income for the three months ended June 30, 2026, increased to $740 million from $444 million in the prior year.
• The Bausch + Lomb segment showed strong performance, with revenues up 9% for the six-month period to $2.64 billion and segment profit increasing by 43% to $612 million.
• The company ended the quarter with $1.84 billion in cash, cash equivalents, and restricted cash.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant goodwill impairment charge and the resulting net loss for the six-month period, despite revenue growth in key segments.

Positives

• Total revenues increased by 13% to $2.85 billion for the three months ended June 30, 2026, compared to $2.53 billion in the prior year.
• Six-month revenues increased by 12% to $5.38 billion compared to $4.79 billion in the prior year.
• Operating income for the three months ended June 30, 2026, improved to $740 million from $444 million in the prior year.
• The Bausch + Lomb segment reported a 9% revenue increase for the six-month period, reaching $2.64 billion, with segment profit up 43% to $612 million.
• The Solta Medical segment saw a significant 38% revenue increase for the three-month period and a 44% increase for the six-month period, driven by acquisitions and volume growth.
• The company's cash, cash equivalents, and restricted cash increased to $1.84 billion as of June 30, 2026.

Negatives

• The company reported a net loss attributable to Bausch Health Companies Inc. of $1.17 billion for the six months ended June 30, 2026, a significant decrease from a net income of $90 million in the prior year.
• A goodwill impairment charge of $1.43 billion was recognized in the six months ended June 30, 2026, primarily impacting the Salix reporting unit.
• The Diversified segment experienced a 5% decrease in revenue for the six-month period.
• The company's provision for income taxes increased significantly to $165 million for the six months ended June 30, 2026, from $51 million in the prior year.

Risks

• The Inflation Reduction Act (IRA) may impact future revenues and cash flows, particularly with the negotiated price for Xifaxan becoming effective in 2027.
• Potential loss of exclusivity for key branded products, such as Xifaxan, between 2026 and 2030, could lead to significant revenue declines.
• Ongoing litigation, including antitrust and intellectual property disputes, could result in material adverse effects on the company's business, financial condition, and results of operations.
• The FDA issued an Official Action Indicated (OAI) for Bausch + Lomb's Tampa, Florida facility, although the company has submitted responses and corrective actions.
• Macroeconomic and geopolitical conditions, including inflation and trade restrictions, could adversely affect the company's business.
• The company faces generic competition for several products, which could lead to significant decreases in sales.

Future Outlook

The company continues to focus on managing its capital structure, directing capital allocation to drive growth in core businesses, improving patient access, and investing in sustainable growth drivers. Management expects to remain in compliance with debt covenants and meet debt service obligations.

Management Comments

• We continue to execute on actions intended to bring out value in our Company.
• Our capital allocation is also driven by our long-term growth strategies.
• We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan.
• We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.

Industry Context

StockSavvy.ai notes that Bausch Health's performance reflects broader trends in the pharmaceutical and medical device sectors, including the impact of strategic acquisitions, the ongoing management of debt, and the challenges posed by patent expirations and generic competition. The significant goodwill impairment highlights the sensitivity of valuations to clinical trial outcomes and market dynamics.

Legal Proceedings

• The company is involved in various legal and administrative proceedings, including securities litigation, antitrust litigation, and intellectual property disputes.
• A significant goodwill impairment of $1.43 billion was recognized due to clinical trial failures for a rifaximin formulation, impacting the Salix reporting unit.
• The company is defending against multiple antitrust lawsuits related to generic pricing and Xifaxan.
• Several intellectual property litigations are ongoing concerning products like Xifaxan, Cabtreo, and Relistor Oral tablets.
• Product liability lawsuits involving Shower to Shower powder remain pending, with indemnification obligations from Johnson & Johnson.
• The FDA issued an Official Action Indicated (OAI) for Bausch + Lomb's Tampa, Florida facility, with corrective actions underway.

Stakeholder Impact

• Shareholders may be concerned by the significant goodwill impairment and net loss, despite revenue growth.
• Creditors will monitor the company's ability to manage its substantial debt obligations.
• Patients may be impacted by the company's decision to exit certain channels and potential future pricing pressures due to healthcare reform.

Next Steps

• Continue to manage capital structure and evaluate opportunities to simplify the business.
• Focus on driving growth within core businesses through strategic acquisitions, R&D investment, and licensing agreements.
• Monitor the impact of the Inflation Reduction Act and potential generic competition.
• Await FDA response regarding the Bausch + Lomb Tampa facility re-inspection.

Key Dates

Recommendation

While revenue growth and improved operating income in the current quarter are positive, the significant goodwill impairment and net loss for the six-month period, coupled with ongoing litigation and regulatory risks, warrant a cautious 'hold' stance. The company's ability to manage its debt and navigate future patent expirations and regulatory changes will be critical.

Keywords

Bausch Health, 10-Q, Quarterly Report, Pharmaceuticals, Medical Devices, Eye Health, Salix, Bausch + Lomb